Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC105P Combination Study in Ovarian Cancer
NCT01624493Phase 2Withdrawn
- Sponsor
- Hoosier Cancer Research Network
- Start
- Oct 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of BNC105P in ovarian cancer (2 arms), sponsored by Hoosier Cancer Research Network. Primary endpoints: Maximum Tolerated Dose at 12 months and Objective Response Rate at 12 months. Planned start Oct 2012; status: withdrawn.
02
Drugs
BNC105P
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01624493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624493.